61 related articles for article (PubMed ID: 20832294)
1. Suppression of ovarian function in combination with an aromatase inhibitor as treatment for advanced breast cancer in pre-menopausal women.
Cheung KL; Agrawal A; Folkerd E; Dowsett M; Robertson JF; Winterbottom L
Eur J Cancer; 2010 Nov; 46(16):2936-42. PubMed ID: 20832294
[TBL] [Abstract][Full Text] [Related]
2. Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer.
Record H; Clelland E; Rothschild HT; Kaur M; Chien AJ; Melisko M; Rugo HS; Mujir F; Huppert L; Mukhtar RA
NPJ Breast Cancer; 2023 Oct; 9(1):88. PubMed ID: 37884561
[TBL] [Abstract][Full Text] [Related]
3. Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer.
McCann KE; Goldfarb SB; Traina TA; Regan MM; Vidula N; Kaklamani V
NPJ Breast Cancer; 2024 Jan; 10(1):8. PubMed ID: 38242892
[TBL] [Abstract][Full Text] [Related]
4. Goserelin-Induced Chemical Burn: A Case Report and Review of the Literature.
Mahadevan A; Warnecke B; Chiao E; Nafissi N; Parajuli K; Rijal N; Parajuli R
Cureus; 2023 Sep; 15(9):e45692. PubMed ID: 37745751
[TBL] [Abstract][Full Text] [Related]
5. Goserelin plus letrozole as first- or second-line hormonal treatment in premenopausal patients with advanced breast cancer.
Yao S; Xu B; Li Q; Zhang P; Yuan P; Wang J; Ma F; Fan Y
Endocr J; 2011; 58(6):509-16. PubMed ID: 21532215
[TBL] [Abstract][Full Text] [Related]
6. Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer.
Bartsch R; Bago-Horvath Z; Berghoff A; DeVries C; Pluschnig U; Dubsky P; Rudas M; Mader RM; Rottenfusser A; Fitzal F; Gnant M; Zielinski CC; Steger GG
Eur J Cancer; 2012 Sep; 48(13):1932-8. PubMed ID: 22459763
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of goserelin plus anastrozole in premenopausal women with advanced or recurrent breast cancer refractory to an LH-RH analogue with tamoxifen: results of the JMTO BC08-01 phase II trial.
Nishimura R; Anan K; Yamamoto Y; Higaki K; Tanaka M; Shibuta K; Sagara Y; Ohno S; Tsuyuki S; Mase T; Teramukai S
Oncol Rep; 2013 May; 29(5):1707-13. PubMed ID: 23446822
[TBL] [Abstract][Full Text] [Related]
8. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Francis PA; Pagani O; Fleming GF; Walley BA; Colleoni M; Láng I; Gómez HL; Tondini C; Ciruelos E; Burstein HJ; Bonnefoi HR; Bellet M; Martino S; Geyer CE; Goetz MP; Stearns V; Pinotti G; Puglisi F; Spazzapan S; Climent MA; Pavesi L; Ruhstaller T; Davidson NE; Coleman R; Debled M; Buchholz S; Ingle JN; Winer EP; Maibach R; Rabaglio-Poretti M; Ruepp B; Di Leo A; Coates AS; Gelber RD; Goldhirsch A; Regan MM;
N Engl J Med; 2018 Jul; 379(2):122-137. PubMed ID: 29863451
[TBL] [Abstract][Full Text] [Related]
9. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12.
Gnant M; Mlineritsch B; Stoeger H; Luschin-Ebengreuth G; Knauer M; Moik M; Jakesz R; Seifert M; Taucher S; Bjelic-Radisic V; Balic M; Eidtmann H; Eiermann W; Steger G; Kwasny W; Dubsky P; Selim U; Fitzal F; Hochreiner G; Wette V; Sevelda P; Ploner F; Bartsch R; Fesl C; Greil R;
Ann Oncol; 2015 Feb; 26(2):313-20. PubMed ID: 25403582
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer and incident cardiovascular events: A systematic analysis at the nationwide level.
Gue YX; Bisson A; Bodin A; Herbert J; Lip GYH; Fauchier L
Eur J Clin Invest; 2022 Jun; 52(6):e13754. PubMed ID: 35113450
[TBL] [Abstract][Full Text] [Related]
11. Optimizing treatment selection, and sequencing decisions for Management of HR-Positive, HER2-Negative advanced breast cancer - Proceedings from breast cancer expert group meeting.
Dawood S; Konstantionva M; Dent R; Perazzo F; Kim SB; Villarreal-Garza C; Franco S; Dai MS; Simon S
BMC Proc; 2021 Aug; 15(Suppl 10):15. PubMed ID: 34372853
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer in adolescents and young adults.
Johnson RH; Anders CK; Litton JK; Ruddy KJ; Bleyer A
Pediatr Blood Cancer; 2018 Dec; 65(12):e27397. PubMed ID: 30156052
[TBL] [Abstract][Full Text] [Related]
13. Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature.
Tancredi R; Furlanetto J; Loibl S
Oncologist; 2018 Aug; 23(8):974-981. PubMed ID: 29934412
[TBL] [Abstract][Full Text] [Related]
14. Aromatase inhibitors in premenopausal women with breast cancer: the state of the art and future prospects.
Pistelli M; Mora AD; Ballatore Z; Berardi R
Curr Oncol; 2018 Apr; 25(2):e168-e175. PubMed ID: 29719441
[TBL] [Abstract][Full Text] [Related]
15. Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer.
Lambertini M; Del Mastro L; Viglietti G; Pondé NF; Solinas C; de Azambuja E
Curr Treat Options Oncol; 2017 Jan; 18(1):4. PubMed ID: 28185173
[TBL] [Abstract][Full Text] [Related]
16. Defining the optimal sequence for the systemic treatment of metastatic breast cancer.
Mestres JA; iMolins AB; Martínez LC; López-Muñiz JI; Gil EC; de Juan Ferré A; Del Barco Berrón S; Pérez YF; Mata JG; Palomo AG; Gregori JG; Pardo PG; Mañas JJ; Hernández AL; de Dueñas EM; Jáñez NM; Murillo SM; Bofill JS; Auñón PZ; Sanchez-Rovira P
Clin Transl Oncol; 2017 Feb; 19(2):149-161. PubMed ID: 27314861
[TBL] [Abstract][Full Text] [Related]
17. Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy.
Bellet M; Gray KP; Francis PA; Láng I; Ciruelos E; Lluch A; Climent MA; Catalán G; Avella A; Bohn U; González-Martin A; Ferrer R; Catalán R; Azaro A; Rajasekaran A; Morales J; Vázquez J; Fleming GF; Price KN; Regan MM
J Clin Oncol; 2016 May; 34(14):1584-93. PubMed ID: 26729437
[TBL] [Abstract][Full Text] [Related]
18. Phase II Trial of Goserelin and Exemestane Combination Therapy in Premenopausal Women With Locally Advanced or Metastatic Breast Cancer.
Wang J; Xu B; Yuan P; Ma F; Li Q; Zhang P; Cai R; Fan Y; Luo Y; Li Q
Medicine (Baltimore); 2015 Jul; 94(26):e1006. PubMed ID: 26131799
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of exemestane in the treatment of breast cancer.
Zucchini G; Geuna E; Milani A; Aversa C; Martinello R; Montemurro F
Int J Womens Health; 2015; 7():551-63. PubMed ID: 26064072
[TBL] [Abstract][Full Text] [Related]
20. Luteinizing hormone-releasing hormone agonist plus an aromatase inhibitor as second-line endocrine therapy in premenopausal females with hormone receptor-positive metastatic breast cancer.
Tanaka K; Tokunaga E; Yamashita N; Taketani K; Akiyoshi S; Morita M; Maehara Y
Surg Today; 2014 Sep; 44(9):1678-84. PubMed ID: 24218007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
